Title: A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
Journal: Clinical pharmacokinetics 20180101
Title: Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Journal: Cancer discovery 20160701
Title: Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Journal: British journal of cancer 20160315
Title: Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Journal: Cancer cell 20160314
Title: Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Journal: Discovery medicine 20160101
Title: Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20150901
Title: A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Journal: Cancer biology & therapy 20130701
Title: The requirement for cyclin D function in tumor maintenance.
Journal: Cancer cell 20121016
Title: Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.
Journal: Cancer cell 20121016
Title: Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Journal: Cell cycle (Georgetown, Tex.) 20120715
Title: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.
Journal: Cancer cell 20100713
Title: The landscape of somatic copy-number alteration across human cancers.
Journal: Nature 20100218
Title: Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.?2016 Mar 22;7(12):14803-13.
Title: Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.
Title: Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.
